Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSL001
MIFTS: 62

Measles

Categories: Infectious diseases, Rare diseases, Skin diseases, Smell/Taste diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Measles

About this section

MalaCards integrated aliases for Measles:

Name: Measles 12 74 52 29 54 42 3 43 15 17 71 32
Morbilli 12
Rubeola 52

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Smell/Taste diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8622
ICD9CM 34 055
MeSH 43 D008457
NCIt 49 C96406
SNOMED-CT 67 14189004
UMLS 71 C0025007
Sources

Summaries for Measles

About this section
MedlinePlus : 42 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary : Measles, also known as morbilli, is related to subacute sclerosing panencephalitis and rubella, and has symptoms including fever, cough and conjunctivitis. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Bleomycin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and brain, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Measles virus, which is transmitted by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

CDC : 3 Measles is a highly contagious virus that can lead to complications.

Wikipedia : 74 Measles is a highly contagious infectious disease caused by measles virus. Symptoms usually develop... more...

Sources

Related Diseases for Measles

About this section

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 789)
# Related Disease Score Top Affiliating Genes
1 subacute sclerosing panencephalitis 34.0 TLR3 SLAMF1 IL6 IL2 IFNA1 IFIH1
2 rubella 33.7 TLR4 TLR3 IL6 IL2 IFNB1 IFNAR2
3 mumps 32.8 TLR3 STAT1 IL6 IL2 IFNB1 IFNAR2
4 exanthem 32.1 IL6 IL2 IFNA1 IFIH1
5 encephalitis 31.7 TLR3 TLR2 STAT1 IL6 IFNB1 IFNA1
6 conjunctivitis 31.6 TLR3 IL6 IL2
7 chickenpox 31.6 TLR3 TLR2 STAT1 IL6 IL2 IFNB1
8 otitis media 31.3 TLR4 TLR2 IL6 IL2
9 appendicitis 31.3 TLR4 IL6 IL2
10 crohn's disease 31.2 TLR4 TLR2 IL6 IL2
11 vaccinia 31.2 STAT1 IL6 IL2 IFNB1 IFNA1 EIF2AK2
12 yellow fever 31.2 STAT1 IL6 IFNB1
13 japanese encephalitis 31.2 TLR3 IFNB1 IFNA1 CD209
14 diarrhea 31.2 TLR4 STAT1 IL6 IL2 IFNB1 IFNA1
15 hepatitis a 31.2 TLR4 TLR3 IFNA1
16 pneumonia 31.1 TLR4 TLR3 TLR2 IL6 IL2 IFNB1
17 meningitis 31.1 TLR4 TLR2 IL6 IL2 CD46
18 newcastle disease 31.1 TLR3 IFNB1 IFNA1 EIF2AK2 DDX58
19 dengue virus 31.0 IFIH1 DDX58 CD209
20 hepatitis 31.0 IFNAR2 IFNA1 IFIH1 EIF2AK2 DDX58
21 bacterial infectious disease 31.0 TLR4 TLR3 TLR2 IL6 IFNB1
22 chikungunya 31.0 STAT1 IL6 DDX58 CD209
23 bronchitis 31.0 TLR4 TLR2 STAT1 IL6
24 keratitis, hereditary 30.9 TLR4 TLR2 IL6
25 bacterial pneumonia 30.9 TLR4 TLR3 TLR2 IL6
26 viral pneumonia 30.9 TLR3 IL6 IFNB1 DDX58
27 rabies 30.9 TLR3 STAT1 IFNA1 DDX58
28 dengue disease 30.9 IFNB1 IFNA1 CD209
29 bronchiolitis 30.9 TLR4 TLR3 TLR2 IL6 IFNA1
30 inflammatory bowel disease 30.8 TLR4 TLR3 TLR2 STAT1 IL6 IL2
31 stomatitis 30.8 TLR4 IL6 IL2 IFNB1 IFNA1 EIF2AK2
32 myocarditis 30.8 TLR4 TLR3 IL6 IL2 IFNA1
33 west nile virus 30.8 IFNA1 IFIH1 DDX58 CD209
34 viral encephalitis 30.7 TLR3 IL6 IFNB1 IFNA1 DDX58
35 human immunodeficiency virus type 1 30.7 TLR3 STAT1 IL2 HLA-A CD209 ADAR
36 herpes simplex 30.7 TLR3 TLR2 STAT1 IL6 IFNB1 IFNA1
37 keratoconjunctivitis 30.6 IL6 IL2 CD46
38 bronchiolitis obliterans 30.6 TLR4 TLR2 IL6
39 dermatitis, atopic 30.6 TLR4 TLR3 TLR2 STAT1 IL6 IL2
40 plague 30.6 TLR4 TLR3 TLR2 IL6 DDX58
41 toxic shock syndrome 30.6 TLR4 TLR2 IL6 IL2
42 demyelinating disease 30.6 IL6 IL2 IFNB1 IFNA1
43 graft-versus-host disease 30.6 IL6 IL2 HLA-A
44 mycobacterium tuberculosis 1 30.6 TLR4 TLR2 STAT1 IFNB1 CD209
45 herpes zoster 30.5 TLR2 IL2 IFNA1 HLA-A
46 hepatitis d 30.5 IFNA1 EIF2AK2 ADAR
47 toxoplasmosis 30.5 TLR4 TLR2 STAT1 IL6
48 neutropenia 30.5 TLR4 IL6 IL2 IFNA1
49 lymphocytic choriomeningitis 30.5 TLR2 IL6 DDX58 ADAR
50 kawasaki disease 30.5 IL6 IL2 FCGR2B

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles
Sources

Symptoms & Phenotypes for Measles

About this section

Symptoms:

12
  • • fever
  • • cough
  • • conjunctivitis
  • • coryza
  • • maculopapular

UMLS symptoms related to Measles:


fever, pruritus, exanthema, koplik spots

MGI Mouse Phenotypes related to Measles:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 ADAR DDX58 EIF2AK2 FCGR2B HLA-A IFIH1
2 immune system MP:0005387 10.22 ADAR DDX58 EIF2AK2 FCGR2B HLA-A IFIH1
3 homeostasis/metabolism MP:0005376 10.18 ADAR DDX58 FCGR2B IFIH1 IFNAR2 IFNB1
4 cellular MP:0005384 10.17 ADAR DDX58 EIF2AK2 FCGR2B IFIH1 IL2
5 mortality/aging MP:0010768 10 ADAR DDX58 EIF2AK2 FCGR2B HLA-A IFIH1
6 liver/biliary system MP:0005370 9.91 ADAR DDX58 FCGR2B IFIH1 IL2 IL6
7 neoplasm MP:0002006 9.65 DDX58 EIF2AK2 IFNAR2 IFNB1 IL2 IL6
8 respiratory system MP:0005388 9.23 FCGR2B IL2 IL6 MSN STAT1 TLR2
Sources

Drugs & Therapeutics for Measles

About this section

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
5
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
6
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
7
Lumefantrine Approved Phase 4 82186-77-4 6437380
8
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
9
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
10
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
11
BCG vaccine Investigational Phase 4
12 Retinol palmitate Phase 4
13 retinol Phase 4
14 Insulin, Globin Zinc Phase 4
15 insulin Phase 4
16 Vaccines Phase 4
17 Anti-Infective Agents Phase 4
18 Antiprotozoal Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Antimalarials Phase 4
21 Trace Elements Phase 4
22 Micronutrients Phase 4
23 Antiviral Agents Phase 4
24 Citrate Phase 4
25 Anthelmintics Phase 4
26 Laxatives Phase 4
27 Cathartics Phase 4
28 Gastrointestinal Agents Phase 4
29 Artemether, Lumefantrine Drug Combination Phase 4
30 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
31
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
32
Sulfamethoxazole Approved Phase 3 723-46-6 5329
33
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
34 Orange Approved Phase 3
35
Zinc Approved, Investigational Phase 3 7440-66-6 32051
36
Proguanil Approved Phase 2, Phase 3 500-92-5 4923
37
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
38
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
39
Petrolatum Approved, Investigational Phase 3 8009-03-8
40
Podophyllin Approved Phase 3 9000-55-9
41
Azithromycin Approved Phase 3 83905-01-5 447043 55185
42
leucovorin Approved Phase 3 58-05-9 6006 143
43
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
44
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
45
Dapsone Approved, Investigational Phase 3 80-08-0 2955
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
47
Chlorproguanil Investigational Phase 3 537-21-3 151170 9571037
48 Anti-Inflammatory Agents Phase 3
49 Anti-Allergic Agents Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 284)
# Name Status NCT ID Phase Drugs
1 A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine Unknown status NCT01486355 Phase 4
2 Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
3 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Unknown status NCT01770119 Phase 4
4 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Unknown status NCT01306006 Phase 4
5 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01644721 Phase 4
6 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01668745 Phase 4
7 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
8 Randomised Trial of Vitamin A Supplementation Given With Routine Childhood Vaccines at National Immunisation Days Unknown status NCT00168623 Phase 4 Vitamin A
9 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
10 Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau Unknown status NCT00168610 Phase 4 Vitamin A
11 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L：A Multi-center Randomized Controlled Trial Unknown status NCT03519568 Phase 4
12 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
13 Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh Completed NCT01700621 Phase 4
14 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
15 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
16 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
17 Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau Completed NCT00168571 Phase 4
18 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
19 Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival Completed NCT00168558 Phase 4
20 Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
21 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
22 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
23 An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age Completed NCT00312858 Phase 4
24 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
25 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
26 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
27 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
28 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
29 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
30 Comparison of Immunization Schedules of Beijing Tiantan Biological's MMR Vaccine in 18-72 Month-Old Children Completed NCT03160820 Phase 4
31 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
32 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
33 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
34 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463684 Phase 4
35 Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination Completed NCT00244673 Phase 4
36 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
37 A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months Completed NCT02253407 Phase 4
38 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
39 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
40 Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Completed NCT00168597 Phase 4 Vitamin A
41 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
42 Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka Completed NCT00463476 Phase 4
43 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
44 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
45 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
46 Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children Completed NCT00968370 Phase 4
47 In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
48 Health Effects of Utilising Curative Health System Contacts to Provide Measles Vaccination - a Randomised Controlled Trial Recruiting NCT04220671 Phase 4
49 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
50 A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children Recruiting NCT03460002 Phase 4

Search NIH Clinical Center for Measles

Cochrane evidence based reviews: measles

Sources

Genetic Tests for Measles

About this section

Genetic tests related to Measles:

# Genetic test Affiliating Genes
1 Measles 29
Sources

Anatomical Context for Measles

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Measles:

19
Skin

MalaCards organs/tissues related to Measles:

40
Testes, Brain, T Cells, Bone, Skin, Eye, B Cells
Sources

Publications for Measles

About this section

Articles related to Measles:

(show top 50) (show all 23197)
# Title Authors PMID Year
1
In the aftermath: the legacy of measles in Samoa. 61 42
32416777 2020
2
Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020. 42 61
32431288 2020
3
Progress Toward Measles Elimination - Eastern Mediterranean Region, 2013-2019. 61 42
32298253 2020
4
Measles virus-induced immunosuppression in SLAM knock-in mice. 54 61
20200244 2010
5
Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. 61 54
20071568 2010
6
Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). 61 54
20042501 2010
7
Development and evaluation of a rapid immunochromatographic test for mumps-specific IgM in oral fluid specimens and use as a matrix for preserving viral nucleic acid for RT-PCR. 61 54
20087926 2010
8
Restriction analysis of otosclerosis-associated CD46 splicing variants. 61 54
19597833 2010
9
Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. 54 61
19806178 2009
10
Laboratory confirmation of measles in elimination settings: experience from the Republic of the Marshall Islands, 2003. 61 54
19274360 2009
11
Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis. 61 54
19319188 2009
12
Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. 54 61
19007958 2009
13
Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. 61 54
18715339 2008
14
Disease-associated novel CD46 splicing variants and pathologic bone remodeling in otosclerosis. 61 54
18677279 2008
15
Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. 54 61
18419254 2008
16
High-density rafts preferentially host the complement activator measles virus F glycoprotein but not the regulators of complement activation. 61 54
18455798 2008
17
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. 54 61
18559536 2008
18
Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. 61 54
18325643 2008
19
[Host genetic factors for the development of SSPE]. 54 61
17695285 2007
20
Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. 61 54
17695519 2007
21
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. 61 54
17492596 2007
22
Expression of measles virus receptors in otosclerotic, non-otosclerotic and in normal stapes footplates. 54 61
17294206 2007
23
Downregulation of human CD46 by adenovirus serotype 35 vectors. 54 61
17377598 2007
24
Current problems of measles control in Japan and Western Pacific Region. 54 61
17368662 2007
25
Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. 54 61
17356690 2007
26
Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. 54 61
17135325 2007
27
Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. 54 61
17070884 2007
28
Detection of circulating antigen with a MAb-based sandwich-ELISA and its comparison with specific IgM detection in sera of patients with hemorrhagic fever with renal syndrome. 61 54
17316085 2007
29
A case of common variable immunodeficiency syndrome associated with Takayasu arteritis. 61 54
17304891 2007
30
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. 61 54
17133484 2006
31
Cloning, expression, and purification of a highly immunogenic recombinant gonadotropin-releasing hormone (GnRH) chimeric peptide. 61 54
17064933 2006
32
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. 54 61
17062694 2006
33
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. 54 61
16645169 2006
34
The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. 61 54
16782388 2006
35
Identification of amino acid residues involved in the interaction between measles virus Haemagglutin (MVH) and its human cell receptor (signaling lymphocyte activation molecule, SLAM). 54 61
16889684 2006
36
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. 61 54
16728275 2006
37
Assessment of the performance of a definition of a suspected measles case: implications for measles surveillance. 61 54
16723063 2006
38
Immunosuppression caused by measles virus: role of viral proteins. 61 54
16237742 2006
39
Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. 61 54
16223530 2005
40
Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. 54 61
16260741 2005
41
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. 61 54
15920733 2005
42
Evaluation of diagnostic markers for measles virus infection in the context of an outbreak in Spain. 54 61
16207972 2005
43
Gene expression profiles in peripheral blood mononuclear cells from patients with subacute sclerosing panencephalitis using oligonucleotide microarrays. 61 54
16036810 2005
44
Localization of regions in CD46 that interact with adenovirus. 61 54
15919905 2005
45
CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. 54 61
15845515 2005
46
Rescue and propagation of fully retargeted oncolytic measles viruses. 54 61
15685166 2005
47
Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? 54 61
15659756 2005
48
Expression of the interferon-alpha/beta-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis. 54 61
15337611 2004
49
Measles virus receptors: SLAM and CD46. 61 54
15248250 2004
50
Variation in vaccine response in normal populations. 61 54
15165177 2004
Sources

Variations for Measles

About this section
Sources

Expression for Measles

About this section
Search GEO for disease gene expression data for Measles.
Sources

Pathways for Measles

About this section

Pathways related to Measles according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.89 TLR4 TLR3 TLR2 STAT1 IL6 IL2
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.39 STAT1 IL6 IL2 IFNB1 IFNAR2 IFNA1
3
Human cytomegalovirus infection 36
Show member pathways
 12.93 TLR4 TLR3 TLR2 STAT1 IL6 IFNB1
4
Allograft rejection 1 36
Show member pathways
 12.83 STAT1 IL6 IL2 IFNA1 HLA-A
5
PI3K-Akt signaling pathway 36
Show member pathways
 12.83 TLR4 TLR3 TLR2 STAT1 IL6 IL2
6
Pathways in cancer 36
12.82 STAT1 IL6 IL2 IFNAR2 IFNA1
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.82 TLR4 TLR3 TLR2 STAT1 IL6 IL2
8
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.77 TLR4 TLR3 TLR2 STAT1 IL6 IFNB1
9
NF-KappaB Family Pathway 63
Show member pathways
 12.73 TLR4 TLR3 TLR2 IL6 IL2 EIF2AK2
10
T cell receptor signaling pathway 36
Show member pathways
 12.61 TLR4 TLR2 STAT1 IL6 IL2
11
NF-kappaB Signaling 4
12.61 TLR3 TLR2 STAT1 IL2 IFNA1 IFIH1
12
Th17 cell differentiation 36
Show member pathways
 12.6 TLR4 TLR2 STAT1 IL6 IL2
13
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.6 TLR3 IL6 IFNB1 IFNA1 IFIH1 DDX58
14
Interferon gamma signaling 65
Show member pathways
 12.57 STAT1 IFNB1 IFNAR2 IFNA1 HLA-A EIF2AK2
15
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.52 IL2 IFNB1 IFNAR2 IFNA1 HLA-A
16
JAK-STAT signaling pathway 36
Show member pathways
 12.5 STAT1 IL6 IL2 IFNB1 IFNAR2 IFNA1
17
Herpes simplex virus 1 infection 36
12.39 TLR3 TLR2 STAT1 IL6 IFNB1 IFNAR2
18
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.32 STAT1 IL6 IL2 IFNB1 IFNAR2 IFNA1
19
Measles 36
Show member pathways
 12.31 TLR4 TLR3 TLR2 STAT1 SLAMF1 MSN
20
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.3 TLR4 TLR3 TLR2 IL6 IFNB1
21
Toll Comparative Pathway 63
Show member pathways
 12.29 TLR4 TLR3 STAT1 IL6
22
NOD-like receptor signaling pathway 36
12.29 TLR4 STAT1 IL6 IFNB1 IFNAR2 IFNA1
23
Colorectal Cancer Metastasis 63
12.23 TLR4 TLR3 TLR2 STAT1 IL6
24
Bacterial infections in CF airways 22
Show member pathways
 12.23 TLR4 TLR2 STAT1 IL6 IFNB1
25
Necroptosis 36
Show member pathways
 12.23 TLR4 TLR3 STAT1 IFNB1 IFNAR2 IFNA1
26
C-type lectin receptor signaling pathway 36
Show member pathways
 12.21 STAT1 IL6 IL2 CD209
27
Phagosome 36
12.18 TLR4 TLR2 HLA-A FCGR2B CD209
28
Tuberculosis 36
12.18 TLR4 TLR2 STAT1 IL6 IFNB1 IFNA1
29
MAPK Pathway 70
Show member pathways
 12.09 TLR4 TLR3 TLR2 STAT1 IL2
30
Osteoclast differentiation 36
12.06 STAT1 IFNB1 IFNAR2 FCGR2B
31
Yersinia infection 36
12.03 TLR4 IL6 IL2 IFNB1
32
IL27-mediated signaling events 1
Show member pathways
 12.03 TLR4 TLR3 TLR2 STAT1 IL6 IL2
33
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.01 SLAMF1 IL6 IL2 CD209
34
Th17 Differentiation 64
Show member pathways
 11.93 TLR4 TLR3 TLR2 STAT1 IL6
35
Interferon Pathway 63
11.92 STAT1 IL6 IFNB1 IFNAR2 IFNA1
36
Rheumatoid arthritis 36
11.84 TLR4 TLR2 IL6
37
Phagocytosis of Microbes 63
11.8 TLR4 TLR3 TLR2
38
Dendritic Cells Developmental Lineage Pathway 64
11.8 SLAMF1 IL6 IL2 IFNB1 CD209
39
Glucocorticoid receptor regulatory network 1
11.77 STAT1 IL6 IL2
40
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.64 IL2 IFNAR2 HLA-A
41
Legionellosis 36
11.61 TLR4 TLR2 IL6
42
Malaria 36
11.55 TLR4 TLR2 IL6
43
all-trans-Retinoic Acid Mediated Apoptosis 63
11.52 IL6 IFNB1 IFNA1
44
Type II interferon signaling (IFNG) 1
11.4 STAT1 IFNB1 EIF2AK2
45
Cytokines and Inflammatory Response 1
11.28 IL6 IL2 IFNB1
46
Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics 60
Show member pathways
 11.16 STAT1 IFNAR2 EIF2AK2 DDX58 ADAR
Sources

GO Terms for Measles

About this section

Cellular components related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 TLR4 TLR3 TLR2 IFNAR2 HLA-A FCGR2B
2 cell surface GO:0009986 9.23 TLR4 TLR3 TLR2 SLAMF1 MSN HLA-A

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TLR4 TLR3 TLR2 STAT1 IL6 IL2
2 immune response GO:0006955 10.16 TLR4 TLR2 IL6 IL2 HLA-A FCGR2B
3 positive regulation of gene expression GO:0010628 10.11 TLR4 TLR3 TLR2 MSN IL6 DDX58
4 inflammatory response GO:0006954 10.1 TLR4 TLR3 TLR2 IL6 FCGR2B
5 adaptive immune response GO:0002250 10.1 SLAMF1 IL2 IFNB1 IFNA1 HLA-A CD46
6 cytokine-mediated signaling pathway GO:0019221 10.06 STAT1 IL6 IL2 IFNB1 IFNAR2 IFNA1
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TLR4 TLR3 TLR2 IL6 EIF2AK2
8 defense response GO:0006952 10 TLR3 STAT1 IFNB1 IFNA1 FCGR2B
9 innate immune response GO:0045087 10 TLR4 TLR3 TLR2 SLAMF1 IFIH1 HLA-A
10 cellular response to interferon-gamma GO:0071346 9.95 TLR4 TLR3 TLR2 STAT1
11 positive regulation of inflammatory response GO:0050729 9.94 TLR4 TLR3 TLR2 IL2
12 viral entry into host cell GO:0046718 9.93 SLAMF1 NECTIN4 CD46 CD209
13 positive regulation of JNK cascade GO:0046330 9.93 TLR4 TLR3 SLAMF1 FCGR2B
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.92 TLR4 TLR3 TLR2 EIF2AK2
15 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL2 CD46 CD209
16 viral process GO:0016032 9.9 STAT1 SLAMF1 NECTIN4 MSN IFIH1 HLA-A
17 humoral immune response GO:0006959 9.88 IL6 IFNB1 IFNA1
18 positive regulation of interleukin-6 production GO:0032755 9.88 TLR4 TLR3 TLR2 IL6 DDX58
19 type I interferon signaling pathway GO:0060337 9.88 STAT1 IFNB1 IFNAR2 IFNA1 HLA-A ADAR
20 positive regulation of tumor necrosis factor production GO:0032760 9.87 TLR4 TLR3 TLR2
21 positive regulation of interferon-gamma production GO:0032729 9.87 TLR4 IL2 HLA-A
22 response to virus GO:0009615 9.87 TLR3 IFNB1 IFNAR2 IFIH1 EIF2AK2 DDX58
23 toll-like receptor signaling pathway GO:0002224 9.86 TLR4 TLR3 TLR2
24 positive regulation of interleukin-6 secretion GO:2000778 9.85 TLR4 TLR2 IFIH1 DDX58
25 positive regulation of interleukin-12 production GO:0032735 9.83 TLR4 TLR3 TLR2
26 positive regulation of interleukin-10 production GO:0032733 9.83 TLR4 TLR2 CD46
27 response to exogenous dsRNA GO:0043330 9.83 TLR3 IFNB1 IFNA1 DDX58
28 positive regulation of interferon-beta production GO:0032728 9.83 TLR4 TLR3 TLR2 IFIH1 DDX58
29 cellular response to interferon-beta GO:0035458 9.82 TLR3 STAT1 IFNB1
30 positive regulation of interleukin-8 production GO:0032757 9.81 TLR4 TLR3 TLR2 DDX58
31 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.8 TLR4 TLR2 STAT1
32 cellular response to exogenous dsRNA GO:0071360 9.8 TLR3 IFNB1 IFIH1 DDX58
33 I-kappaB phosphorylation GO:0007252 9.77 TLR4 TLR3 TLR2
34 positive regulation of chemokine production GO:0032722 9.77 TLR4 TLR3 TLR2 IL6 EIF2AK2
35 positive regulation of interferon-alpha production GO:0032727 9.76 TLR4 STAT1 IFIH1 DDX58
36 response to interferon-alpha GO:0035455 9.75 IFNAR2 EIF2AK2 ADAR
37 immune system process GO:0002376 9.73 TLR4 TLR3 TLR2 SLAMF1 IL2 IFIH1
38 positive regulation of regulatory T cell differentiation GO:0045591 9.72 IL2 CD46
39 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL6 IL2
40 positive regulation of interferon-alpha secretion GO:1902741 9.71 IFIH1 DDX58
41 cellular response to lipoteichoic acid GO:0071223 9.71 TLR4 TLR2
42 response to interferon-beta GO:0035456 9.71 STAT1 IFNAR2
43 positive regulation of interferon-beta biosynthetic process GO:0045359 9.71 TLR4 TLR3
44 positive regulation of response to cytokine stimulus GO:0060760 9.71 IFIH1 DDX58
45 detection of virus GO:0009597 9.71 TLR3 IFIH1 DDX58
46 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.7 TLR4 TLR3
47 positive regulation of interferon-beta secretion GO:0035549 9.69 IFIH1 DDX58
48 positive regulation of toll-like receptor signaling pathway GO:0034123 9.68 TLR3 TLR2
49 interleukin-10 production GO:0032613 9.68 TLR2 CD46
50 positive regulation of matrix metallopeptidase secretion GO:1904466 9.67 TLR4 TLR2

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TLR4 TLR3 TLR2 STAT1 SLAMF1 NECTIN4
2 identical protein binding GO:0042802 9.81 TLR4 TLR3 TLR2 STAT1 SLAMF1 NECTIN4
3 cytokine activity GO:0005125 9.71 IL6 IL2 IFNB1 IFNA1
4 amyloid-beta binding GO:0001540 9.61 TLR4 TLR2 FCGR2B
5 virus receptor activity GO:0001618 9.56 SLAMF1 NECTIN4 CD46 CD209
6 signaling receptor activity GO:0038023 9.43 TLR4 TLR3 TLR2 SLAMF1 NECTIN4 CD46
7 lipopolysaccharide receptor activity GO:0001875 9.32 TLR4 TLR2
8 double-stranded RNA binding GO:0003725 9.1 TLR3 MSN IFIH1 EIF2AK2 DDX58 ADAR
Sources

Sources for Measles

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....